1012057-13-4

Basic information

• Product Name: thyl 2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)acetate
• Synonyms: thyl 2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)acetate
• CAS NO: 1012057-13-4
• Molecular Weight: 405.813
• Mol File: 1012057-13-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: thyl 2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: thyl 2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)acetate(1012057-13-4)
• EPA Substance Registry System: thyl 2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)acetate(1012057-13-4)

Safety Data

• Hazardous Substances Data: 1012057-13-4(Hazardous Substances Data)

Upstream product

• 105-36-2 ethyl bromoacetate 
• 184475-35-2 gefitinib 
• 179688-52-9 6-hydroxy-7-methoxyquinazolin-4(3H)-one 
• 13794-72-4 3H-6,7-dimethoxyquinazolin-4-one 
• 230955-75-6 6-acetoxy-4-chloro-7-methoxyquinazoline 
• 26759-46-6 methyl 2-amino-4,5-dimethoxybenzoate 
• 184475-71-6 4-(3-chloro-4-fluorophenylamino)-6-hydroxy-7-methoxyquinazoline 

Downstream Products

• 1012054-52-2 2-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide 
• 1373944-84-3 C₂₈H₂₄ClFN₆O₂ 
• 1373944-75-2 2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)acetic acid 
• 1373944-81-0 C₂₈H₂₂ClFN₆O₃ 

Relevant articles and documents

Compound for simultaneously inducing EGFR and PARP protein degradation as well as preparation method and application thereof

The invention discloses a compound capable of simultaneously inducing EGFR and PARP protein degradation as well as a preparation method and an application thereof, and belongs to the field of medicinal chemistry. The invention provides an application of a series of novel dual-targeting degradation compounds with two independent inhibitor units and an E3 ligase ligand or pharmaceutically acceptable salts, hydrates, stereoisomers or prodrugs thereof in preparation of drugs for treating or preventing tumors. The compound provided by the invention can effectively induce E3 ligase dependent degradation of EGFR and PARP in pancreatic cancer cell lines and 1299 cells at the same time, and can effectively inhibit the growth of cancer cells. The target diversity of advanced cancers with tumor heterogeneity and reverse chemotherapy drug resistance can be solved. The method provided by the invention provides a new treatment mode for treatment of EGFR and PARP mediated tumors and/or other diseases.

QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF

Quinazoline derivatives represented by general formula (1) and quinazoline complexes as protein kinase inhibitors, and their preparation methods are provided. Wherein, in general formula (1), at least one of R and R′ is a group containing an atom capable

TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives that are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The tartrate salts may further act as HDAC inhibitors.